Details of the Drug

General Information of Drug (ID: DMYXT2U)

Drug Name
Secukinumab
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Alopecia ED70 Phase 2 [2]
Atopic dermatitis EA80 Phase 2 [2]
Dry eye disease 9E1Z Phase 2 [2]
Multiple sclerosis 8A40 Phase 2 [2]
Psoriatic arthritis FA21 Phase 2 [2]
Rheumatoid arthritis FA20 Phase 2 [2]
Type-1 diabetes 5A10 Phase 2 [2]
⏷ Show the Full List of Indication(s)
Affected Organisms
Humans and other mammals
ATC Code
L04AC10: Secukinumab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Sequence
>Secukinumab Heavy Chain (CAS 875356-43-7)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYY
VGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRG
TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK e format="FASTA">&gt
Secukinumab Light Chain (CAS 875356-44-8)EIVLTQSPGTLSLSPGERA
TLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL
EPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
QGLSSPVTKSFNRGEC
Cross-matching ID
UNII
DLG4EML025
DrugBank ID
DB09029
TTD ID
D0Q0OD
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate